Page last updated: 2024-10-30

loxoprofen and Carcinoma, Lewis Lung

loxoprofen has been researched along with Carcinoma, Lewis Lung in 1 studies

loxoprofen: RN given refers to parent cpd without isomeric designation; structure in first source
loxoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-oxocyclopentyl)methyl]phenyl group. A prodrug that is rapidly converted into its active trans-alcohol metabolite following oral administration.

Carcinoma, Lewis Lung: A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kanda, A1
Ebihara, S1
Takahashi, H1
Sasaki, H1

Other Studies

1 other study available for loxoprofen and Carcinoma, Lewis Lung

ArticleYear
Loxoprofen sodium suppresses mouse tumor growth by inhibiting vascular endothelial growth factor.
    Acta oncologica (Stockholm, Sweden), 2003, Volume: 42, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Lewis Lung; Carc

2003